Glenmark Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
GLENMARK
Pharmaceuticals
Screen Glenmark Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹2113.10
▲
38.50 (1.86%)
Share Price BSE
₹2113.10
▲
38.60 (1.86%)
Market Cap
₹57,179.53 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
6.00
EPS (TTM)
₹37.11
Dividend Yield
0.12%
Debt to Equity
0.22
52W High
₹2226.70
52W Low
₹1278.95
Operating Margin
5.00%
Profit Margin
0.12%
Revenue (TTM)
₹3,232.00
EBITDA
₹164.00
Net Income
₹4.00
Total Assets
₹16,050.00
Total Equity
₹8,849.00
Glenmark Pharmaceuticals Share Price History - Stock Screener Chart
Screen GLENMARK historical share price movements with interactive charts. Analyze price trends and patterns.
Glenmark Pharmaceuticals Company Profile - Fundamental Screener
Screen Glenmark Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GLENMARK shares.
Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several countries. Glenmark is involved in drug discovery for new chemical and biological entities, with molecules in various stages of development. It has a strong generics business serving markets like the US and Europe, and an active pharmaceutical ingredients business selling to over 80 countries. The company has made several acquisitions and licensing deals to expand its product portfolio and global reach. Glenmark has launched numerous products across various therapeutic segments and markets, including innovative combinations and first-to-market generics. It has a substantial pipeline of ANDAs filed with the US FDA and continues to receive approvals for new generic products.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Glenn Saldanha
ISIN
INE935A01035
Website
https://www.glenmarkpharma.com
Glenmark Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GLENMARK balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16,050 | 14,359 | 19,372 | 17,083 | 15,604 | 14,685 | 13,296 | 12,595 | 11,764 | 10,193 |
| Current Assets | 9,296 | 7,428 | 9,874 | 8,282 | 7,360 | 6,804 | 6,697 | 6,989 | 6,875 | 5,904 |
| Fixed Assets | 4,487 | 4,210 | 6,202 | 5,887 | 5,129 | 5,029 | 3,670 | 3,030 | 2,755 | 2,594 |
| Liabilities | ||||||||||
| Total Liabilities | 16,050 | 14,359 | 19,372 | 17,083 | 15,604 | 14,685 | 13,296 | 12,595 | 11,764 | 10,193 |
| Current Liabilities | 1,234 | 693 | 4,487 | 2,956 | 4,338 | 4,489 | 3,670 | 4,144 | 4,569 | 2,564 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 8,849 | 7,848 | 9,839 | 9,438 | 7,064 | 6,070 | 5,605 | 5,163 | 4,492 | 3,629 |
| Share Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves & Surplus | 8,821 | 7,820 | 9,446 | 9,058 | 7,036 | 6,042 | 5,577 | 5,135 | 4,464 | 3,601 |
Screen GLENMARK income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,232 | 3,086 | 6,204 | 3,814 | 3,255 | 3,440 | 3,333 | 3,062 | 3,018 | 3,281 | 2,625 | 3,068 | 2,903 | 3,069 | 3,272 |
| Expenses | 3,068 | 3,007 | 5,072 | 3,005 | 2,656 | 2,832 | 2,787 | 3,402 | 2,651 | 3,071 | 2,792 | 2,638 | 2,346 | 2,539 | 2,626 |
| EBITDA | 164 | 79 | 1,132 | 808 | 599 | 608 | 546 | -340 | 367 | 211 | -168 | 430 | 558 | 530 | 646 |
| Operating Profit % | 5.00% | 2.00% | 16.00% | 0.00% | 18.00% | 17.00% | 16.00% | -15.00% | 12.00% | 3.00% | -13.00% | 11.00% | 14.00% | 15.00% | 14.00% |
| Depreciation | 125 | 130 | 141 | 151 | 118 | 120 | 123 | 135 | 142 | 141 | 147 | 132 | 147 | 146 | 152 |
| Interest | 67 | 58 | 67 | 149 | 40 | 49 | 52 | 109 | 112 | 122 | 134 | 87 | 60 | 83 | 97 |
| Profit Before Tax | 8 | 96 | 967 | 555 | 462 | 473 | 456 | -542 | 151 | -6 | -403 | 270 | 408 | 337 | 435 |
| Tax | 4 | 49 | 357 | 1,770 | 122 | 118 | 108 | -139 | -22 | 56 | -72 | 97 | 197 | 58 | 144 |
| Net Profit | 4 | 47 | 610 | -1,214 | 340 | 355 | 348 | -403 | 173 | -62 | -331 | 173 | 211 | 279 | 291 |
| EPS | 0.16 | 1.66 | 21.63 | -43.17 | 12.06 | 12.55 | 12.33 | -15.18 | 5.31 | -2.90 | -12.45 | 5.51 | 6.82 | 9.23 | 9.66 |
Glenmark Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GLENMARK cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -828 | -265 | 625 | 1,109 | 1,131 | 1,392 | 1,324 | 1,648 | 657 | 345 |
| Investing Activities | 58 | 4,387 | -515 | -316 | -662 | -774 | -883 | -1,003 | -1,001 | -950 |
| Financing Activities | 787 | -3,906 | -78 | -521 | -442 | -445 | -739 | -469 | 543 | 699 |
| Net Cash Flow | 17 | 215 | 33 | 272 | 28 | 174 | -297 | 177 | 199 | 93 |
Screen GLENMARK shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.64% | 46.65% |
| FII Holding | 20.73% | 20.62% | 23.16% | 23.51% | 23.05% | 20.98% | 21.38% | 23.71% |
| DII Holding | 18.61% | 17.64% | 14.60% | 13.85% | 13.21% | 13.92% | 13.36% | 10.92% |
| Govt Holding | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public Holding | 10.81% | 11.69% | 12.32% | 12.65% | 13.61% | 14.58% | 14.83% | 14.77% |
| Other Holding | 3.16% | 3.37% | 3.24% | 3.31% | 3.45% | 3.83% | 3.75% | 3.92% |
| Shareholder Count | 198,789 | 190,210 | 192,724 | 195,059 | 193,949 | 192,630 | 199,451 | 209,931 |
Glenmark Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen GLENMARK dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹2.50 | 0.12% |
| 2024-March | ₹2.50 | 0.16% |
| 2023-March | ₹2.50 | 0.26% |
| 2022-March | ₹2.50 | 0.56% |
| 2021-March | ₹2.50 | 0.57% |
| 2020-March | ₹2.50 | 0.54% |
| 2019-March | ₹2.00 | 0.97% |
| 2018-March | ₹2.00 | 0.31% |
| 2017-March | ₹2.00 | 0.38% |
Glenmark Pharmaceuticals Index Membership - Market Screener Classification
Screen GLENMARK by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Glenmark Pharmaceuticals Market Events Screener - Corporate Actions
Screen GLENMARK market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 2.50 /share | 49.01% | ||
| Dividend | ₹ 2.50 /share | -1.14% | ||
| Dividend | ₹ 2.50 /share | 40.83% | ||
| Annual General Meeting | NA | 3.71% | ||
| Dividend | ₹ 2.50 /share | 69.51% | ||
| Annual General Meeting | NA | -0.47% | ||
| Dividend | ₹ 2.50 /share | -13.54% | ||
| Annual General Meeting | NA | 4.61% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -0.74% |
| 2025-10-03 | 2025-10-03 | Dividend | ₹ 2.50 /share | -3.56% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -1.86% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | 2.35% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -1.75% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -8.04% |
Glenmark Pharmaceuticals Competitors Screener - Peer Comparison
Screen GLENMARK competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Glenmark Pharmaceuticals Company Announcements - News Screener
Screen GLENMARK latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-30 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-12-01 | Update On The Companys Chhatrapati Sambhajinagar (Aurangabad) Facility | View |
| 2025-11-27 | Update On The Companys Monroe North Carolina (USA) Facility | View |
| 2025-11-25 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-14 | Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September 2025 | View |
| 2025-11-14 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-03 | Closure of Trading Window | View |
| 2025-11-03 | Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-01 | Completion Of Transfer Of Companys Consumer Care Business | View |